- Home
- BIRK vs ROIV Comparison
BIRK vs ROIV Comparison
Compare BIRK & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRK
- ROIV
- Stock Information
- Founded
- BIRK 1774
- ROIV 2014
- Country
- BIRK United Kingdom
- ROIV United Kingdom
- Employees
- BIRK N/A
- ROIV N/A
- Industry
- BIRK
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- BIRK
- ROIV Health Care
- Exchange
- BIRK Nasdaq
- ROIV Nasdaq
- Market Cap
- BIRK 8.8B
- ROIV 7.8B
- IPO Year
- BIRK 2023
- ROIV N/A
- Fundamental
- Price
- BIRK $49.45
- ROIV $11.28
- Analyst Decision
- BIRK Strong Buy
- ROIV Buy
- Analyst Count
- BIRK 12
- ROIV 4
- Target Price
- BIRK $67.75
- ROIV $17.50
- AVG Volume (30 Days)
- BIRK 2.0M
- ROIV 6.6M
- Earning Date
- BIRK 05-15-2025
- ROIV 08-07-2025
- Dividend Yield
- BIRK N/A
- ROIV N/A
- EPS Growth
- BIRK 152.58
- ROIV N/A
- EPS
- BIRK 1.45
- ROIV N/A
- Revenue
- BIRK $2,114,754,647.00
- ROIV $29,053,000.00
- Revenue This Year
- BIRK $19.19
- ROIV $2.64
- Revenue Next Year
- BIRK $15.95
- ROIV $378.09
- P/E Ratio
- BIRK $33.87
- ROIV N/A
- Revenue Growth
- BIRK 19.89
- ROIV N/A
- 52 Week Low
- BIRK $40.56
- ROIV $8.73
- 52 Week High
- BIRK $64.78
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- BIRK 35.08
- ROIV 53.61
- Support Level
- BIRK $51.57
- ROIV $11.25
- Resistance Level
- BIRK $52.98
- ROIV $11.82
- Average True Range (ATR)
- BIRK 1.51
- ROIV 0.33
- MACD
- BIRK -0.63
- ROIV -0.00
- Stochastic Oscillator
- BIRK 8.52
- ROIV 52.97
About BIRK Birkenstock Holding plc
Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. It sells its products through two main channels: business-to-business (B2B) which comprises sales made to established third-party store networks, and direct-to-consumer (DTC) which comprises sales made on globally owned online stores through the Birkenstock.com domain and sales made in Birkenstock retail stores. The company's reportable segments are based on its regional hubs and include: the Americas which is also its key revenue-generating segment; Europe; and Australia, Japan, India, China, and the United Arab Emirates (APMA).
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.